Compare Novo Nordisk A/S (NVO) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Workday Inc — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $200.69B), while Workday Inc trades at $185.98 (market cap $44.89B). The key difference: Novo Nordisk A/S is far larger — about 4.5× Workday Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| NVO | WDAY | |
|---|---|---|
Market Cap | $200.69B | $44.89B |
Sector | Health | Technology |
52-Week High | $63.98 | $247.69 |
52-Week Low | $35.29 | $112.55 |
Enterprise Value | $215.49B | $45.26B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Workday (WDAY) trades at $186.28, down 4.86% today but has rallied 49.7% over three months on strong Q2 earnings beats and AI momentum. The stock shows bullish technical signals with support at $183 and resistance at $191. Fundamentally, revenue grew to $8.45B in 2025 with expanding margins, though valuation ratios remain elevated at P/E 37.94 and P/S 4.73. Recent news highlights Workday's eleventh consecutive leadership position in Gartner's HCM Magic Quadrant and growing AI adoption.
The outlook remains positive with analyst consensus at Buy (50.62%) and $204.52 price target, representing 9.8% upside. Key opportunities include AI-driven subscription growth and margin expansion, while risks involve competitive pressures from AI-native startups and execution challenges in sustaining profitability gains amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
